Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
2/27/2013 9:32:07 AM
More...
|
Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5/31/2012 12:28:08 PM
More...
|
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
7/22/2011 6:15:40 AM
More...
|
Taiho Pharmaceutical's Teysuno(TM) (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
3/15/2011 8:17:44 AM
More...
|
Taiho Pharmaceutical: Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
12/17/2010 6:41:43 AM
More...
|
Taiho Pharmaceutical Selects Medidata Solutions, Inc. Rave for Global Trials
7/28/2008 9:04:18 AM
More...
|
Taiho Pharmaceutical and Sanofi-Aventis (France) (SASY.PA) Release: S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone
6/4/2007 2:47:24 PM
More...
|
Makoto Life Sciences, Inc. Signs $20 Million Research Collaboration With Taiho Pharmaceutical
8/2/2006 5:03:18 PM
More...
|
Taiho Pharmaceutical And Sanofi-Aventis (France) (SASY.PA) Conclude Licensing Agreement For Oral Pyrimidine Fluoride-Derived Anticancer Agent TS-1
7/10/2006 3:14:28 PM
More...
|
The Day In Review: Sanofi-Aventis (France) (SASY.PA) In-Licenses Japanese Cancer Drug
7/5/2006 6:45:50 PM
More...
|
|